Gefapixant

Gefapixant
Clinical data
Trade names	Lyfnua
Other names	MK-7264
ATC code	R05DB29 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Identifiers
	IUPAC name 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide;
CAS Number	1015787-98-0;
PubChem CID	24764487;
DrugBank	DB15097;
ChemSpider	58828660;
UNII	6K6L7E3F1L;
KEGG	D11349;
ChEMBL	ChEMBL3716057;
CompTox Dashboard (EPA)	DTXSID401337212 ;
ECHA InfoCard	100.258.106
Chemical and physical data
Formula	C14H19N5O4S
Molar mass	353.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC;
	InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19); Key:HLWURFKMDLAKOD-UHFFFAOYSA-N;

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.^[1] It acts as an antagonist of the P2RX3 receptor.^[2]^[3]^[4]